UDP-Gal: N-acetylglucosamine β 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis

7Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

As compared to cutaneous leishmaniasis, vaccination against visceral leishmaniasis (VL) has received limited attention. In this study, we demonstrate for the first time that an UDP-Galactose: N-acetylglucosamine β 1-4 galactosyltransferase (GenBank Accession No. EF159943) expressing attenuated LD clonal population (A-LD) is able to confer protection against the experimental challenge with the virulent LD AG83 parasite. A-LD was also effective in established leishmania infection. The vaccinated animals showed both cell mediated (in vitro T-cell proliferation, and DTH response) and humoral responses (Th1 type). These results demonstrate the potential of the attenuated clones as an immunotherapeutic and immunoprophylactic agent against visceral leishmaniasis. © 2009 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Bhaumik, S. K., Singh, M. K., Karmakar, S., & De, T. (2009). UDP-Gal: N-acetylglucosamine β 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. In Glycoconjugate Journal (Vol. 26, pp. 663–673). https://doi.org/10.1007/s10719-008-9212-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free